公开(公告)号：US20150169840A1

公开(公告)日：2015-06-18

申请号：US14237226

申请日：2012-08-03

Applicant: Kenneth Kupfer ,  Richard C. Sangeorge ,  Jerome Mcaleer ,  Kevin Keegen ,  David Kinniburgh Lang

Inventor： Kenneth Kupfer ,  Richard C. Sangeorge ,  Jerome Mcaleer ,  Kevin Keegen ,  David Kinniburgh Lang

IPC: G06F19/00 ,  G01N33/53 ,  A61B5/02

CPC classification number: G16H50/30 ,  A61B5/02 ,  G01N33/53 ,  G01N33/6887 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/58 ,  G01N2800/325 ,  G01N2800/50 ,  G01N2800/52 ,  G16B20/00 ,  G16B40/00 ,  G16H40/63

Abstract: The present invention provides methods and compositions for monitoring of subjects suffering from, or being evaluated for, heart failure. A filtered Natriuretic peptide time-series, alone or in combination with other clinical indicia such as weight gain, can be used to estimate a patient's hazard (risk of decompensation). The cumulative integral of Natriuretic peptide concentration can be used to estimate cumulative hazard (risk times exposure) over longer periods of exposure, e.g., 14 day periods, or 30 day periods.

Abstract translation: 本发明提供了用于监测患有或被评估为心力衰竭的受试者的方法和组合物。 可以使用过滤的利尿钠肽时间序列，单独或与其他临床指标组合，例如体重增加，以估计患者的危险（失代偿风险）。 利尿钠肽浓度的累积积分可用于估计长时间暴露的累积危险（风险时间暴露），例如14天或30天。

公开(公告)号：USD621059S1

公开(公告)日：2010-08-03

申请号：US29295631

申请日：2007-10-02

Applicant: Claus Marquordt ,  David William Taylor ,  Colin Hanna ,  David Kinniburgh Lang ,  Brian McGuigan ,  Colin Boyd ,  Jonathan Chua Cheng Lam ,  Allen Lai Siew Kong ,  Chun Keat Ooi

Designer： Claus Marquordt ,  David William Taylor ,  Colin Hanna ,  David Kinniburgh Lang ,  Brian McGuigan ,  Colin Boyd ,  Jonathan Chua Cheng Lam ,  Allen Lai Siew Kong ,  Chun Keat Ooi

公开(公告)号：US20090130771A1

公开(公告)日：2009-05-21

申请号：US11988595

申请日：2006-07-19

Applicant: Oliver William Hardwicke Davies ,  David Kinniburgh Lang ,  John William Dilleen ,  Phillip Lowe ,  Steven Howell ,  Christopher John Slevin

Inventor： Oliver William Hardwicke Davies ,  David Kinniburgh Lang ,  John William Dilleen ,  Phillip Lowe ,  Steven Howell ,  Christopher John Slevin

IPC: G01N27/00 ,  B01J19/00 ,  G01N21/00 ,  C12M1/00

CPC classification number: G01N33/54326

Abstract: An assay device includes a first reagent including a magnetic particle and a second reagent including detectable component. The first and second reagent can each independently bind to an analyte in a sample. Applying a magnetic field can selectively concentrate the detectable component in a detection zone, where a detectable change ca be measured and related to the amount of analyte in the sample.

Abstract translation: 测定装置包括包含磁性颗粒的第一试剂和包含可检测组分的第二试剂。 第一和第二试剂可以各自独立地结合样品中的分析物。 应用磁场可以将可检测组分选择性地浓缩在检测区域中，其中可测量可检测的变化并与样品中分析物的量相关。